News | May 30, 2022
Glenmark Pharma reports revenue growth of 5.6% YoY in Q4
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights how blockchain ensures the authenticity of products thereby, improves trust, traceability, and transparency across key sectors
Dr Jitendra Singh said, the Biotech Park would act as a hub for incubation of new ideas
The ABDM public dashboard is a one-stop solution for information on the mission’s progress up to state/UT level
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
Subscribe To Our Newsletter & Stay Updated
